positive
Recently
AstraZeneca Q3 revenue climbs 10 % as drug‑sales momentum holds
AstraZeneca beats Q3 targets, sustains growth and reiterates US$80 bn sales goal by 2030.
AstraZeneca beat expectations in Q3 2025 with core earnings at US $2.38 per share (+12 % YoY) and revenue of US $15.19 billion (+10%).
Strong performance from its cancer, cardiovascular and kidney‑disease treatment portfolios helped maintain full‑year guidance of high single‑digit revenue growth and low double‑digit EPS growth.
The company reiterated ambitions for US $80 billion in annual sales by 2030, pointing to its U.S. listing plans and investments in local manufacturing as part of global expansion strategy.